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ABSTRACT
Introduction: methicillin- and also vancomycin (glycopeptide)-resistant Gram-positive organisms have 
emerged as an increasingly problematic cause of hospital-acquired infections, also spreading into the com-
munity. Vancomycin (glycopeptide) resistance has emerged primarily among Enterococci, but the MIC val-
ues of vancomycin for the entire Staphylococcus species are also increasing worldwide. Material and Meth-
ods: the aim of our review is to evaluate the efficacy and tolerability of newer antibiotics with activity against 
methicillin-resistant and glycopeptide-resistant Gram-positive cocci, on the ground of our experience at a 
tertiary care metropolitan Hospital, and the most recent literature evidences in this field. Results: Quinupris-
tin-dalfopristin, linezolid, daptomycin, and tigecycline show an excellent in vitro activity, comparable to the 
activity of vancomycin and teicoplanin for methicillin-resistant staphylococci, and superior to the one that 
vancomycin for vancomycin-resistant isolates. Dalbavancin, televancin, and oritavancin are new lipoglyco-
peptide agents with excellent activity against Gram-positive cocci, and have superior pharmacodynamics 
properties compared to vancomycin. We review the bacterial spectrum, clinical indications and practical 
use, pharmacologic properties, and expected adverse events and contraindications associated with each of 
these novel antimicrobial agents, compared with the present standard of care. Discussion: linezolid activity 
is substantially comparable to that of vancomycin in patients with methicillin-resistant Staphylococcus aureus 
(MRSA) pneumonia, although its penetration into the respiratory tract is exceptionally elevated. Tigecy-
cline has activity against both Enterococus species and MRSA; it is also active against a broad spectrum of 
Enterobacteriaceae and anaerobes, which allows for use intraabdominal, diabetic foot and surgical infections. 
Daptomycin has a rapid bactericidal activity for Staphylococcus aureus and it is approved in severe complica-
tions, such as bacteremia and right-sided endocarditis. It cannot be used to treat pneumonia and respiratory 
diseases, due to its inactivation in the presence of pulmonary surfactant. 
Keywords: resistant gram-positive cocci, staphylococci, enterococci, pneumococci, streptococci, epi-
demiology, clinical issues, novel antimicrobial compounds, characteristics, literature evidences.
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Novel pharmaceutical molecules against emerging  
resistant gram-positive cocci
INFECTIONS CAUSED BY GRAM-POSI-
TIVE COCCI. AN OUTLINE OF THEIR 
ANTIBIOTIC RESISTANCE PROFILE
Gram-positive cocci have re-emerged as pre-
dominant pathogens of human hosts within 
the past 10-15 years. After the introduction of 
penicillin over 60 years ago, infections by Sta-
phylococcus aureus, Streptococcus pyogenes, and 
Streptococcus pneumoniae finally became treat-
able. Within a short period of time, however, S. 
aureus developed resistance to penicillin. As a 
consequence, penicillinase-resistant penicillins 
were successfully introduced with in the early 
1960’s. Concomitantly, resistance emerged for 
the penicillinase-resistant penicillins, and fi-
nally methicillin (oxacillin)-resistant S. aureus 
(MRSA) became a major hospital-acquired 
pathogen. Vancomycin (belonging to the class 
of glycopeptides) remained an active agent 
against MRSA and coagulase-negative Staphy-
lococci, so that it was increasingly used dur-
ing the subsequent years, until now. From the 
1990’s to the present, however, the emergence 
of resistance to vancomycin also occurred in 
a significant proportion.1-3 First among these 
organisms were Enterococcus faecium and En-
terococcus faecalis.4 Subsequently, vancomycin 
(glycopeptide)-resistant enterococci (VRE) 
became a major hospital-acquired patho-
gen. In the past several years, MRSA were also 
spreading clonally into the community (the 
so-called “CA-MRSA”), leading to increased 
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use of vancomycin-teicoplanin therapy.5 In the late 1990’s, 
glycopeptide resistance was reported for coagulase-negative 
Staphylococci6 and then, S. aureus (the so-called vancomy-
cin-intermediate S. aureus, or VISA, and the so-called glyco-
peptide-intermediate S. aureus, or GISA). The first reported 
isolation of VISA occurred in Japan in 19977 and more than 
one hundred VISA isolates have been reported in the subse-
quent years.8 In the year 2002, three vancomycin-resistant S. 
aureus (VRSA) strains isolated from clinical specimens of 
American patients were found to have high level resistance 
to vancomycin (MIC >32 ug/mL).9 Although a number of 
cases of VRSA have since been described,10 these isolates for-
tunately have not yet become widespread.
The re-emergence of Gram-positive cocci has been well 
established in the setting of hospital-acquired infections, but 
community-acquired infections due to MRSA have become 
increasingly problematic during the last years.11-13 Foreign 
body infections and bacteremia caused by coagulase-nega-
tive Staphylococci have also increased during time.14 As a re-
sult, vancomycin-teicoplanin usage has increased in both in-
patients and outpatients. Although the majority of S. aureus 
strains remain susceptible in vitro to vancomycin, its efficacy 
against methicillin-sensitive S. aureus (MSSA) is inferior to 
that of penicillinase-resistant penicillins and beta-lactam 
derivatives as a whole.15,16
Actually, MRSA is born as a multi-drug resistant patho-
gen. Resistance to the macrolides, lincosamides, aminogly-
cosides, and all beta-lactam agents as a group, as well as fluo-
roquinolones, is also seen when MRSA is of clinical concern. 
Rifampin should not be used as a single agent due to rapid 
emergence of resistance in these microorganisms, while 
doxycycline and trimethoprim-sulfamethoxazole (cotri-
moxazole) are bacteriostatic rather than bactericidal in their 
mechanisms of action.17
S. aureus is well known to be a virulent and invasive path-
ogen. It produces a variety of pyrogenic toxins and superan-
tigens which contribute to its overall virulence.18 The pres-
ence of the Panton-Valentine leukocidin may predispose to 
invasive skin and soft tissue infections, and also necrotizing 
pneumonias and other necrotizing infectious localizations. 
MRSA infection often has its origin from a localized skin 
infection, with subsequent contiguous or hematogenous 
spread to lungs, heart (endocarditis), central nervous sys-
tem (CNS), and sometimes bones and joints and other or-
gans and sites.19 The prolonged duration of treatment with 
vancomycin or teicoplanin for severe infections, like endo-
carditis and osteomyelitis, may lead to more frequent and 
severe adverse effects (especially nephropathy, serum elec-
trolyte imbalance, and myelotoxicity). While VISA/GISA 
and VRSA infections have only rarely been reported, clinical 
hetero-resistant populations of VISA (with strains showing 
MIC values > 4-16 mcg/mL) have been isolated following 
prolonged administration of glycopeptides. Moreover, phar-
macodynamics of vancomycin may have led to unappreci-
ated under dosing of vancomycin, therefore predisposing 
to microbial resistance.20 Coagulase-negative Staphylococci 
have the capability to produce a glycocalyx enabling them 
to attach to prosthetic materials.21 Biofilm formation on 
the surfaces of medical devices (i.e. prosthetic devices, cen-
tral vascular catheters), provides a protected environment 
for coagulase-negative Staphylococci; this biofilm forma-
tion impedes antibiotic penetration and reduces target site 
formation.21,22 As expected, catheter-related blood stream in-
fections, CNS ventricular shunt infections, prosthetic joint 
infections, and prosthetic valve endocarditis are commonly 
caused by coagulase-negative Staphylococci.23
The large majority of these microorganisms usually are or 
become resistant to methicillin. Intermediate resistance to van-
comycin was first reported among coagulase-negative Staphy-
lococci several years before it occurred among S. aureus strains. 
Unlike S. aureus, infections by coagulase-negative Staphylococci 
on prosthetic hardware tend to be insidious and more chronic. 
Therapy often requires a combined medical- surgical approach 
with removal of the infected device and prolonged duration 
(usually exceeding four weeks) of antibiotic therapy thereafter. 
Vancomycin-resistant Enterococci (VRE) are primarily as-
sociated with healthcare institutional acquisition in patients 
with co-morbid conditions. Since their peak incidence around 
the year 2000, several new antibiotics with excellent activity 
against VRE have been introduced into clinical practice in the 
meantime.
On the other hand, S. pneumoniae is the most frequent 
cause of community acquired pneumonia (CAP). It accounts 
for at least one third of patients with CAP. The crude incidence 
of this common pathogen rises to greater than 50%, if respira-
tory culture with Gram stains and urinary antigen for S .pneu-
moniae are systematically performed. Associated bacteremia 
occurs in 20% of pneumococcal pneumonias and mortality 
is notably higher than for other respiratory pathogen. In vitro 
resistance of S. pneumoniae to penicillin as currently defined 
by Clinical Laboratory Standards Institute (CLSI) criteria, does 
not necessarily correlate with clinical failure. Specifically, peni-
cillins have been favourably efficacious for pneumonia caused 
by penicillin-resistant pneumococci.24,25 These resistant isolates 
are often also resistant to macrolides, and in vitro resistance to 
macrolide does appear to correlate with clinical outcome.26,27 
In adult patients, S. pneumoniae also represents the most 
common cause of meningitis. Empiric therapy for meningitis 
with ceftriaxone and vancomycin pending antibiotic suscepti-
bility testing is often employed. Data from a large scale observa-
tional study of pneumococcal meningitis suggests that combi-
nation therapy may be superior to monotherapy .28 
Groups A Streptococci (whose leading organism is Strepto-
coccus pyogenes), as well as other beta-hemolytic Streptococci, 
are often associated with life-threatening infections, especially 
involving the skin and soft tissues. Group B, C, F, and G beta-
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hemolytic Streptococci can also cause invasive infection and 
becteremia. Streptococcus agalactiae (belonging to group B 
Streptococci), is a common cause of neonatal sepsis. Fortunate-
ly, susceptibility to penicillin remains stable for the majority of 
the above-mentioned Streptococci.
EPIDEMIOLOGICAL EXPERIENCE AT A MAJOR 
TERTIARY CARE HOSPITAL IN NORTHERN ITALY
A prospective, microbiological surveillance study is ongoing 
for a decade at our academic Hospital (S. Orsola-Malpighi 
Hospital, Bologna, Italy), in order to check the epidemio-
logical-clinical evolution of bacterial and fungal infections 
occurring among inpatients. All microorganisms isolated 
and identified from sterile sites (i.e. blood cultures, pro-
tected bronchoalveolar lavage, urine culture, and so on), 
are systematically tested for in vitro susceptibility against a 
consistent panel of antimicrobial compounds, and data are 
reported quarterly (A. Nanetti and S. Ambretti, unpublished 
data). Each bacterial isolate cultured from a single patient 
within one month is counted only once.
Some data regarding in vitro sensitivity rates of Staphylo-
coccus aureus and Enterococci from the year 2005 to the first 
nine months of the year 2008 are reported in Table 1.
With regard to S. aureus, we underline a progressive re-
duction of methicillin resistance rate (from 56.8% of strains 
in the year 2005 up to 44.7% of overall tested strains in the 
year 2008), while we confirm a maintained 100% suscep-
tibility to all available glycopeptides. Of major interest, the 
introduction of novel guidelines for a correct antimicrobial 
use in medicine and surgery seemed to lead to an appar-
ently progressive reduction of the frequency of antibiotic-
resistant strains, as demonstrated by an increased mean in 
vitro susceptibility rate against almost all tested compounds 
demonstrated in the year 2008, versus years 2005-2007, to-
gether with an apparent progressive trend toward reduced 
resistances during the examined temporal span (years 2005 
to 2008). Furthermore, elevated sensitivity rates are also 
found for a number of “older” molecules, like cotrimoxa-
zole (87.9% to 98.2%), chloramphenicol (83.5% to 88.6%), 
followed by rifampicin (60.2% to 80.4%), clindamycin 
Table 1. Microbiological figures from patients hospitalized at our tertiary-care hospital (S. Orsola-Malpighi 
Hospital, Bologna, Italy), year 2005-2008
In vitro antimicrobial susceptibility of Staphylococcus aureus strains isolated from inpatients (years 2005-2008) 
Antibiotic susceptibility Year 2005 Year 2006 Year 2007 Year 2008
 (190 strains) (167 strains) (131 strains) (Jan. to Sep.)
    (103 strains)
Penicillin 7.9 7.8 9.9 7.8
Amoxicillin-clavulanate 43.2 48.5 48.9 55.3
Cefotaxime/Ceftriaxone 42.9 48.5 48.9 55.3
Methicillin/Oxacillin 43.2 48.5 49.6 55.3
Erithromycin 34.2 48.5 51.9 55.3
Clindamycin 34.9 48.5 51.9 54.4
Chloramphenicol 84.7 88.6 87.8 83.5
Rifampicin 60.2 64.0 62.1 80.4
Cotrimoxazole 87.8 98.2 93.1 95.1
Gentamicin 31.1 41.0 43.5 49.5
Vancomycin/Teicoplanin 100.0 100.0 100.0 100.0
In vitro antimicrobial susceptibility of Enterococci isolated from inpatients (years 2005-2008)
Antibiotic susceptibility Year 2005 Year 2006 Year 2007 Year 2008
  (206 strains) (151 strains) (155 strains) (Jan. to Sep.)
     (108 strains)
Penicillin 50.0 49.0 51.6 50.9
Ampicillin 50.0 49.0 52.3 51.9
Tetracyclin 46.6 45.0 38.7 38.0
Vancomycin/Teicoplanin 98.1 95.4 94.8 96.3
Linezolid 100,0 100,0 100,0 100,0
Daptomycin N/A N/A N/A 100.0
Quinupristin/Dalfopristin 100,0 100,0 100,0 100,0
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(34.9% to 54.4%), and erythromycin (34.2% to 55.3%). 
These last compounds, which are largely available and 
do not imply increased costs of administration, are ex-
pected to be clinically effective alone and/or in combi-
nation with anti-Gram-positive agents (Table 1).
When examining the temporal trend of isolation of Entero-
cocci (as a group) in the same time period (year 2005, up to Sep-
tember 2008), we notice a full sensitivity to novel compounds 
(i.e. linezolid, daptomycin, and quinupristin/dalfopristin), and 
a maintained in vitro effectiveness of glycopeptides (94.8% to 
98.1%). Vancomycin-resistant Enterococci (also called VRE) 
were isolated infrequently: only 9 cases in the year 2005, 6 in the 
year 2006, 8 in the year 2007, and only three cases in the first 9 
months of the year 2009 (A. Nanetti and S. Ambretti, unpub-
lished data). Also in the case of Enterococci, a number of “older” 
compounds still retain an effective activity against Enterococci, 
as demonstrated by susceptibility rates of penicillin (49.0% to 
51.6%), ampicillin (49.0% to 52.3%), and tetracyclines (38.0% 
to 46.6%). Also in this case, these compounds may act favour-
ably or may be a part of a combination regimen, after in vitro 
sensitivity assays (Table 1).
NOVEL ANTIBACTERIAL AGENTS WITH  
ENHANCED ACTIVITY AGAINST RESISTANT 
GRAM-POSITIVE COCCI
The following antibacterial agents have been approved during 
the last five years: quinupristin/dalfopristin,29-32 linezolid,33,34 
daptomycin,35-37 and tigecycline.38,39 Novel lipoglycopeptide 
agents under study include dalbavancin,40 telavancin, and 
oritavancin.41 Even novel cephalosporins (i.e. cefbiprole), 
and fluroquinolones (i.e. garenofloxacin) with enhanced 
activity against MRSA are in the pipeline. Some features of 
these novel antimicrobial molecule are summarized in Ta-
ble 2 (microbiological spectrum, clinical indication, adverse 
events), and in Table 3 (selected pharmacological features).
Quinupristin/Dalfopristin 
The so-called streptogramin antibiotic, quinupristin/dalfo-
pristin, is a combination of two semisynthetic pristinamy-
cin derivatives, which are represented by quinupristin and 
dalfopristin, in a 30:70 ratio. Resistance to quinupristin/
dalfopristin can occur by several mechanisms increasing 
enzymatic modification, active transport of specific efflux 
Table 2. Novel antimicrobial agents for the management of resistant gram-positive infections. Microbiological, 
clinical, and therapeuticfeatures as of the end of 2008. [In vitro antimicrobial susceptibility of staphylococcus 
aureus strains isolated from inpatients (years 2005-2008)] 
Drug Class  Microbiologically effective on Adverse events  Clinical indications   
   MRS MRS PRS VRE   Blood  Skin-  Hospital- 
   A E P    stream soft acquired 
          tissue pneumonia
Vancomycin Glycopeptide + + + Not VISA- Nephro- and + + + 
       VRSA ototoxicity 
        Red man 
        syndrome
Teicoplanin Glycopeptide + + + Not Van-A N/D + + -
Quinupristin/ Streptogramin + + + E. faecium Hepatic, phlebitis + + - 
Dalfopristin       Artho-myalgias + + -
Linezolid Oxazolidinone + + + + Neuropathy,  + + + 
        myelotixicity,  
        serotonin syndrome
Daptomycin Lipopeptide + + + + Arthro-myalgias,  + + - 
        CPK rise  
Tigecycline Glycopeptide + + + + Nausea, diarrhea  + -
Dalbavancin Glycopeptide + + + Not VAN-A Gastrointestinal,  + + - 
        hypokaleamia
Oritavancin Glycopeptide + + + + N/D - + - 
- - - -
Telavancin Lipoglycopep- + + + + Altered taste, CNS,  - + --
  tide      phlebitis7 
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pumps mediated by an adenosine triphosphate-binding 
protein, and alteration of the target site. Resistance is rare for 
Streptococci and Enterococcus faecium.42 This streptogramin 
combination acts synergistically to inhibit bacterial protein 
synthesis at the ribosome level. Quinupristin/dalfopristin 
is therefore active against Staphylococcus aureus (including 
MRSA strains), Streptococcus pneumoniae, and Gram-pos-
itive anaerobes such as Clostridium spp., Peptococcus spp., 
and Peptostreptococcus spp. It is effective against vancomy-
cin-sensitive as well as vancomycin-resistant Enterococcus 
faecium (VREF), but has little in vitro activity against En-
terococcus faecalis, so it cannot be recommended until final 
speciation of Enterococcal organisms is concluded. Dalfo-
pristin/quinipristin association inhibits cytochrome P450 
3A4, and can inhibit agents metabolized through this path-
way. Dosage adjustments may be needed in patients with 
hepatic dysfunction. Renal function has minimal impact on 
the agent’s pharmacokinetics. A post-antibiotic effect is ob-
served in 4-5 hours at 4X MIC for Staphylococci, 7-9 hours 
for Streptococci, and only 4 hours for Enterococci.43
The registered clinical indications for quinupristin/dalfo-
pristin use include intra-abdominal infections, bacteremia, 
urinary tract infection and skin and soft tissue infections 
in which Enterococci may play a relevant pathogenic role. 
Overall clinical success rate for patients with vancomycin-
resistant E. faecium (VREF) proved to be 74%, while overall 
clinical and bacteriological success rate was 66%.44 Patients 
with bacteremia, those on mechanical ventilation, and those 
undergoing surgery had a worse outcome as might be ex-
pected.44 The most common and notable adverse events were 
arthralgias and myalgias, as well as vasculitis. In a compara-
tive clinical trial of therapy for Gram-positive skin and soft 
tissue infections, S. aureus was the most frequent pathogen 
isolated. The clinical success rate of quinupristin/dalfopris-
tin was comparable (68%) to the comparator agents (71%) 
(cefazolin, oxacillin or vancomycin).45 A higher incidence of 
drug-related adverse events occurred with quinopristin/dal-
fopristin as compared to other agents.46 For those patients 
receiving comparator agents, the most common reason for 
discontinuation was treatment failure (12%).46 Furthermore, 
quinupristin/dalfopristin was compared to vancomycin in 
patients with hospital-acquired pneumonia.47 Successful 
outcomes were similar at 56% for quinupristin/dalfopris-
tin and 58% for vancomycin. The bacteriologic success rate 
was identical for both antibiotic groups, at around 54% of 
treated cases. Quinupristin/dalfopristin has been also used 
to treat patients infected by S. aureus intolerant to or failing 
standard therapies.48 
Ninety patients were treated for an average of 28 days 
with a 71% clinical outcome of cure or improvement and 
bacteriologic outcome of eradication or presumed eradica-
tion. Infections included bone and joint, skin and soft tissue, 
bacteremia, endocarditis, and respiratory tract involvement. 
Adverse events included mainly arthralgias (11%), myalgias 
(9%), and nausea (9%). However, in patients with hepatic 
dysfunction or liver transplantation and concurrent receipt 
of immunosuppressive chemotherapy, the incidence of ar-
thralgias approached 50% of treated subjects.49,50
Linezolid 
Linezolid is an oxazolidinone antibiotic with activity against 
Gram-positive pathogens including VRE, MRSA, and VISA. 
The unique mechanism of action of linezolid involves the 
inhibition of bacterial protein synthesis through binding to 
the domain V regions of the 23 Sr RNA gene 46. Resistance 
to linezolid requires mutations of multiple gene copies, 
and seems an infrequent phenomenon. Linezolid is 100% 
bioavailable when given by either oral or intravenous route. 
Maximal plasma levels are achieved within 1-2 hours after 
oral dosing. Protein binding is only around 30% with free 
Table 3. Novel Antimicrobial Agents for Management of Resistant Gram-positive Infections. Selected Pharma-
cogical Features Updated at the End of 2008 
Drug Class Pharmacodynamics Protein  Elimination  Dosage    
   binding (%) route adjustment
      renal  Hepatic
Vancomycin Glycopeptide AUC/MIC 10-55 Renal +  -
Teicoplanin Glycopeptide AUC/MIC 90 Renal +  -
Quinupristin/ Streptogramin AUC/MIC N/A Hepatic/feces N/A  + 
Dalfopristin     
Linezolid Oxazolidinone AUC/MIC 31 Hepatic N/A  N/A 
Daptomycin Lipopeptide AUC/MIC 92 Renal +  N/A
Tigecycline Glycopeptide Time above MIC 68 Biliary N/A  +
Dalbavancin Glycopeptide AUC/MIC >95 Renal +  N/A
Oritavancin Glycopeptide AUC/MIC N/A Renal Renal  N/A
Telavancin Lipoglycopep- AUC/MIC N/A Renal +  - 
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distribution to well-perfused tissues. The drug does not re-
quire dosage alteration in the presence of renal failure, and 
no interaction exists for cytochrome P450 enzymes (and 
drugs metabolized through this last pathway). Linezolid and 
its two metabolites are decreased with hemodialysis, there-
fore dosing should occur post-dialysis.51 
Linezolid is currently approved for skin and soft tissue 
infections and pneumonia due to susceptible pathogens.52 
In two controlled trials of hospital-acquired pneumonia, a 
trend was seen for linezolid superiority over vancomycin.53,54 
There is little data (mainly based on observational stud-
ies), on the utility of linezolid for either bacteremia,55 or 
osteomyelitis.56,57 
Based on a rabbit model, linezolid does not have suf-
ficient CSF penetration and should not be recommended 
for pneumococcal meningitis.33 However, CNS penetration 
appears adequate to treat CSF shunt infections and brain 
abscesses, too.
The myelotoxicity (especially the thrombocytope-
nia), is the most common serious adverse event caused by 
linezolid;59 it can be ameliorated or prevented by co-admin-
istration of pyridoxine (Vitamin B6).60-63 Both peripheral 
and optic neuropathy have been reported with prolonged 
use greater than four consecutive weeks.64,65 Lactic acidosis 
has also been reported and is not associated with duration 
of administration.65,66 Interaction exists between linezolid 
and serotonin-reuptake inhibitors (antidepressants drugs). 
In these last cases, a minority of patients might develop the 
so-called serotonin syndrome (fever, agitation with mental 
status changes and tremors). Due to its weak activity as a 
monoamine oxidase-inhibitor, linezolid should not be used 
concomitantly with agents, such as tramadol, pethidne, du-
loxetine, venlafaxine, milnacipran, sibutramine, chlorpe-
niramine, brompheniramine, cyproheptadine, citalopram, 
and paroxetine.65-67 Drug metabolites may accumulate in the 
event of severe renal failure.
Daptomycin 
Daptomycin is the first in a new class of antimicrobial 
agents: a lipopeptide antibiotic with activity against S. au-
reus (including methicillin-resistant strains), beta-hemo-
lytic Groups A, B, C, and G Streptococci, and Enterococci, 
including ampicillin- and vancomycin-resistant strains. 
Both vancomycin-resistant Staphylococcus aureus and van-
comycin-resistant Enterococci are susceptible to daptomy-
cin. The mechanism of action of daptomycin is unique as 
the molecule causes a calcium ion dependent disruption of 
bacterial cell membrane potential resulting in an efflux of 
potassium, which inhibits RNA, DNA, and protein synthe-
sis. Rare instances of resistance have occurred in clinical tri-
als, although the mechanism of resistance has not yet been 
clearly identified to date. Daptomycin was shown to have 
a rapidly bactericidal effect in vitro against Gram-positive 
drug-resistant pathogens. Its activity is concentration-de-
pendent and once daily dosing is associated with significant 
post-antibiotic effect.
Daptomycin is highly protein bound (around 92%), with 
a terminal half-life of 8 hours, which allows for once daily 
dosing. Post-antibiotic effect proves to be dose dependent, 
and is reduced in the presence of albumin (i.e. exudates). 
The drug volume of distribution is low (0.1L/kg) and the 
Cmax (54.6mcg/mL) is unchanged at steady state, and is 
achieved by day three of administration in humans. Cmax 
concentrations occur at the end of a 30-minutes infusion. 
Dosage needs to be reduced and dosing interval extended 
to every 48 hours in patients with reduced creatinine clear-
ance <30 mL/min; the same occurs for patients on either 
hemodialysis or peritoneal dialysis; the daptomycin dose is 
in these patients becomes 4 mg/kg every 48 hours. Dapto-
mycin should be administered after hemodialysis as approx-
imately 15% is cleared per 4-hour hemodialysis session. On 
the other hand, no dose adjustments for hepatic dysfunction 
are required.
In early clinical trials conducted in the years 1980’s-
1990’s, daptomycin was given in divided daily doses of 2 mg/
kg every 12 hours for skin and soft tissue infection and 3 
mg/kg every 12 hours for bacteremia, achieving good clini-
cal and bacteriological outcomes. However, rise in serum 
creatine phosphokinase (CPK), with myalgias, and muscle 
weakness led to initial abandonment of this promising an-
tibiotic. However, myopathy was reversible upon drug ces-
sation. With the advent of MRSA infections, daptomycin 
has been re-examined and resurrected, and its dosage has 
been increased to 4 mg/kg daily for skin and soft-tissue 
infection,68 and up to 6 mg/kg daily for bacteremia and en-
docarditis.69 Both indications have been approved by the 
United States FDA. Otherwise, daptomycin is not approved 
for the treatment of bacterial pneumonia; its efficacy is sig-
nificantly compromised by its interaction with pulmonary 
surfactant.70 Significant drug-drug interaction occurs with 
the statins, and patients receiving HMG-CoA reductase in-
hibitors; these drugs should be suspended and avoided while 
the patient is undergoing a daptomycin course.
Tigecycline 
Tigecycline is a novel glycylcycline molecule, which is a de-
rivative of the tetracycline minocycline. Resistance to the 
tetracycline class is classically mediated by ribosomal pro-
tection mechanisms or by active efflux. Tigecycline has more 
potent activity against tetracycline-resistant organisms, and 
maintains a broad antibacterial spectrum against Gran-pos-
itive and also Gram-negative pathogens. Tigecycline binds 
more avidly to the ribosome and either does not induce ef-
flux proteins or is not readily exported by efflux proteins.38 
Resistant clinical isolates were associated with up-regulation 
of chromosomally mediated efflux pumps. Unlike original 
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tetracyclines, tigecycline has a large volume of distribution 
(above 10 L/kg), the protein binding is approximately 68%, 
the terminal half-life of elimination is 36 hours, and less than 
15% of the native drug is excreted unchanged in the urine.
Clinical trials have been conducted in patients with com-
plicated skin and soft tissue infections and intra-abdominal 
infections for which the drug gained its United States FDA 
approval. 
Based on in vitro susceptibility data, tigecycline has a 
broad spectrum of activity against both Gram-positive 
cocci (including methicillin-resistant Staphylococci or 
MRSA, penicillin-resistant Streptococcus pneumoniae, beta-
hemolytic group A and group B Streptococci, Enterococci 
(vancomycin-susceptible ones), and Listeria monocytogenes. 
Unlike other new agents for Gram-positive cocci, tigecycline 
also has extensive activity against Gram-negative patho-
gens, including Haemophilus influenzae, Neisseria spp,11 
Enterobacteriaceae, and non-lactose fermenters other than 
Pseudomonas aeruginosa. The MIC
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 values for Proteus spp., 
Providentia spp., and Burkholderia cepacia is 8 mcg/mL, lim-
iting its utility in infections caused by these afore mentioned 
pathogens.
Tigecycline needs no reduction in renal impairment and 
it is not dialyzable. Patients with severe hepatic dysfunction 
(Child-Pugh stage C liver disease) should receive a lower 
dosage. Tigecycline activity is dependent on the time above 
the MIC, and the drug concentrations should be above the 
MIC values for at least 50% of the dosing interval.
The expected adverse effects of tigeciclyne are primarily 
gastrointestinal in origin, with nausea, vomiting, diarrhea, 
and heartburn as the most frequent. As with all tetracy-
clines, tigecycline is contraindicated for pregnant females 
and for children less than 8 years of age.71 Drug interac-
tions of tigecycline with either digoxin or warfarin do not 
alter the effect of either drug. Tigecycline does not inhibit 
metabolism mediated by the cytochrome P450 isoforms 
IA2, 2C8, 2C9, 2C19, 2D6 and 3A4, so that no drug-drug 
interaction is expected with drugs metabolized by these 
cytochrome isoforms.
Dalbavancin 
Dalbavancin is a true second-generation lipoglycopeptide. 
Its unique pharmacokinetic profile allows once weekly dos-
ing. It is not active against VRE, but has an excellent activ-
ity against MRSA, S. pyogenes and S. pneumoniae as well as 
vancomycin-susceptible Enterococci. It is bactericidal and 
synergistic with ampicillin against Van-A type Enterococci. 
The mechanism of action is the inhibition of the cell wall 
peptidoglycan cross-linking. 
The daily dosage is 1000 mg IV once, followed by 500 mg 
IM 7 days later; the terminal half-life of dalbavancin is 9-12 
days in humans due to protein binding greater than 95%. 
Animal models of infection show excellent activity against 
MRSA or GISA endocarditis, penicillin-resistant Streptococ-
cus pneumoniae12 pneumonia or MRSA pouch infection, 
and septicemia due to Staphylococci, Streptococci or En-
terococci. This antibiotic has been evaluated for catheter-
related bacteremia72 and skin and soft tissue infections.73 
Dalbavancin was effective and well tolerated in adult pa-
tients with catheter-related bacteremia caused by coagulase-
negative Staphylococci, MSSA and MRSA in a comparative 
trial with vancomycin. In skin and soft tissue infections, a 
92-94% microbiological and clinical response respectively 
was found in an open label phase 2 comparative dosing 
trial.73 Clinical success at follow-up visits for the two dose 
dalbavancin group was 80% for MRSA versus 50% for com-
parator therapy (which included beta-lactams, clindamycin, 
vancomycin and linezolid, respectively).
Oritavancin 
Oritavancin is another derivative of vancomycin: it is a chlo-
roeremomycin with the substitution of vancosamine by epi-
vancosamine. It has a similar spectrum of activity to vanco-
mycin but with consistently lower MIC values (<1 mg/L). 
No resistance to oritavancin has been observed among S. au-
reus strains including VISA strains, but VAN-A and VAN-B 
strains of Enterococci with reduced susceptibility to orita-
vancin have been obtained in vitro. The known mechanisms 
of resistance of oritavancin are: 1) complete elimination of 
D-Ala-entry precursors; 2) mutations in the VAN Sb sensor 
of VAN B cluster; or 3) the expression of Van Z (the precise 
function of which is still unknown).
Oritavancin shows rapid concentration bactericidal-
dependent activity with a concentration-dependent post-
antibiotic effect exerted against both VRE and MRSA. Ori-
tavancin activity is negatively affected by large inoculum 
and its activity versus VRE was slightly reduced in station-
ary phase or in acidic foci of infection. In animal mod-
els, its efficacy has been demonstrated for experimental 
MRSA endocarditis and S. pneumoniae meningitis.74,75 In 
a reliable endocarditis model, the addition of gentamicin 
proved to be synergistic and able to prevent the emer-
gence of resistant mutants. With regard to skin and soft 
tissue infections, oritavancin proved to be at least equiva-
lent to vancomycin, for both clinical and bacteriological 
cure (about 78% cure rate).76
Telavancin 
Telavancin is a rapidly bactericidal lipoglycopeptide ana-
logue of vancomycin. The mechanism of action of this 
molecule is by inhibition of peptidoglycan chain formation 
through blockage of both the transpeptidation and transgly-
cosylation steps; and by a direct effect on the bacterial mem-
brane dissipating membrane potential and effecting changes 
in cellular permeability.
The in vitro activity of telavancin demonstrates en-
hanced activity against MRSA, penicillin-resistant S. pneu-
moniae, GISA and Van-A type Enterococci. Telavancin 
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achieves a higher volume of distribution into tissues and a 
prolonged half-life.77 A high level of protein binding (93%) 
occurs in human plasma and repetitive dosing does not 
lead to accumulation. The terminal half-life is 7-9 hours at 
doses above 5 mg/kg.78 Telavancin exhibit time-dependent 
killing activity.79
Telavancin and its comparators of vancomycin or beta-
lactam agent have been compared in a phase 2 clinical trial 
for skin and skin-structure infections. Clinical cure rates 
were similar at 92% for telavancin versus 96% for compa-
rator agents. Microbiologic rates of cure were noted to be 
93% in the telavancin group and 95% among the compara-
tor group.80 For complicated skin and soft tissue infections, 
clinical cure rates were at 96% for telavancin and 90% for 
comparator agents. Microbiologic eradication was bet-
ter with telavancin (92%) versus comparator agents (78%, 
p = 0.07).80 Telavancin is currently under assessment in 
phase 3 trials of hospital-acquired pneumonia. 
Adverse events associated with telavancin among evalu-
ated patients included vomiting, paresthesias, and dyspnea. 
Laboratory abnormalities included microalbuminemia and 
a decreased platelet count.81
CLINICAL INDICATIONS OF NOVEL ANTIBI-
OTICS WITH EXPANDED SPECTRUM AGAINST 
RESISTANT GRAM-POSITIVE COCCI
Skin and soft-tissue infections
Skin and soft-tissue infections caused by Gram-positive coc-
ci range from a simple cellulitis to life-threatening necrotiz-
ing fasciitis. All of the newer agents have been studied for 
such infections and have been found to be efficacious (Table 
2). Most of the patients in these studies had less severe infec-
tions than necrotizing fasciitis as that infection requires a 
surgical approach as well as antibiotic therapy. All five FDA-
approved agents, i.e. quinupristin/dalfopristin, linezolid, 
daptomycin, tigecycline, and vancomycin are appropriate 
choices for an effective treatment of Gram-positive patho-
gens. Only tigecycline has activity against Gram-negative 
bacilli pathogens. So, tigecycline may have a major role for 
diabetic foot infections and infected decubitus ulcers which 
may be co-infected by anaerobic bacteria and aerobic Gram-
negative bacilli, in addition to Gram-positive cocci.
Bone and joint infections
With regard to osteomyelitis and joint infections, Gram-
positive cocci largely predominate over other microbial 
pathogens. S. aureus, and both MSSA and MRSA, as well as 
coagulase-negative Staphylococci account for over 50% of 
recovered pathogens. Unfortunately, only few studies have 
prospectively investigated the above-mentioned newer 
antibiotics in these infections.56,57 Aneziokoro et al. evalu-
ated 20 patients who received linezolid for osteomyelitis 
for 6 weeks or more in a retrospective non-comparative 
study.82 Fifty-five percent of cases (11 patients) achieved a 
cure with follow-up periods ranging from 6 to 49 months 
(median of 36 months). Prospective comparative stud-
ies of efficacy in bone and joint infections have not been 
reported to date. In two retrospective studies, 22 patients 
with osteomyelitis and three subjects with septic joint in-
fections were treated with daptomycin.83,84 MRSA was the 
predominant pathogen in over 75% of patients. Daptomy-
cin was used as salvage therapy, and its usual dose was 6 
mg/kg/day. Clinical success rate was about 90%; follow up 
periods were one year or less. Limited data has been pub-
lished with respect to bone and joint infections for dalba-
vancin, tigecycline or quinupristin/dalfopristin in humans. 
In a rabbit model of MRSA osteomyelitis, the combination 
of rifampin and tigecycline was compared to vancomycin 
with or without rifampicin, tigecycline alone, and vanco-
mycin alone.85 All regimens were effective (in about 90% 
of episodes). Untreated rabbits had spontaneous cure in 
26% of cases (4/15). Tigecycline concentrations are higher 
in infected bone than in non-infected bone. A rabbit model 
of quinupristin/dalfopristin prosthetic joint infection with 
MRSA was compared to vancomycin with or without ri-
fampicin, showing an equivalent outcome.86
Pneumonia and lower respiratory tract infections
Pneumonia due to Gram-positive cocci is common. In the 
community, infection is usually due to S. pneumoniae and 
occasionally S. aureus. Hospital-acquired pneumonia (HAP) 
is often caused by MRSA organisms. Linezolid was compa-
rable to vancomycin in the therapy of MRSA-associated 
VAP, although a trend was seen for linezolid superiority.53,54 
Daptomycin is not indicated for pneumonia due to its in-
teraction with surfactant,70 while tigecycline is undergoing 
clinical evaluation. Quinupristin/dalfopristin has been com-
pared to vancomycin for hospital-acquired pneumonia.47 
One hundred and seventy one patients had similar clinical 
response rates of about 57% respectively. Drug discontinua-
tion adverse events occurred more frequently in the quinu-
pristin/dalfopristin group (15%), as compared to vancomy-
cin. Only two isolated of the 87 overall strains were shown 
to have decreased susceptibility to quinupristin/dalfopristin 
during and after treatment.
Intra-abdominal infections
Of the newer antibiotics, only tigecycline has been approved 
for intra-abdominal infections. As mentioned, tigecycline’s 
broader spectrum of activity includes Gram-negative bacilli 
and anaerobic bacilli. Linezolid, daptomycin, and quinu-
pristin/dalfopristin can be used in combination with antibi-
otics with Gram-negative spectrum of activity such as aztre-
onam, and especially carbapenems, fluoroquinolones, and 
aminoglycosides. Of concern, quinupristin/dalfopristin has 
no activity against E. faecalis.
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Bacteremia and endocarditis
Daptomycin and quinipristin/dalfopristin have been ap-
proved by the United States FDA organisms for the treat-
ment of Gram-positive bacteremia. In addition, daptomycin 
has been approved for use in S. aureus right-sided endocar-
ditis.87 Dalbavancin, linezolid, tigecycline and oritavancin 
have not yet been approved for bacteremia due to Gram-
positive cocci. Linezolid has been evaluated for Gram-posi-
tive bacteria.55,88,89 Among 108 bacteremic patients receiving 
linezolid, eradication was seen in 91% and clinical cure was 
seen in 94% of the episodes.55 On the other hand, linezolid 
is still not approved for catheter-related becteremia and en-
docarditis. A randomized study of 726 patients with cath-
eter-related bacteremia received linezolid or vancomycin; 
an excess number of deaths were seen for patients receiving 
linezolid due mainly to Gram-negative rods implicated in 
these infections.90 Based on 23 case reports and three case 
series, a total of 63% (21/33) of patients with endocarditis 
were successfully cured after linezolid administration.91 
MRSA and vancomycin-intermediate S. aureus were the 
most commonly isolated cocci (24.2% and 30.3% of cas-
es, respectively). Five cases were successfully treated with 
linezolid monotherapy.
POTENTIAL SYNERGISTIC INTERACTIONS OF 
NEWER ANTIBIOTICS: IN VITRO STUDIES
In vitro interaction between the new anti-staphylococcal 
antibiotics were virtually always indifferent, therefore lead-
ing to a possible additive effect, although a few experiments 
showed possible (Table 4).89,92-95,98-107 For instance, a synergis-
tic interaction was found for quinupristin/dalfopristin and 
vancomycin in two independent studies.92,93
Table 4. Some experimental studies conducted in vitro or on animal models, regarding possible interactions 
between the different antimicrobial agents effective on Gram-positive Cocci89,92-95,98-107
reference  Combination Pathogens Interaction  
quotation
97  Daptomycin + vancomycin GISA Additive
97  Daptomycin + gentamicin GISA Additive
93  Daptomycin + gentamicin MSSA/MRSA Enhanced time-kill
98  Daptomycin + gentamicin MSSA/MRSA Increased killing
99  Daptomycin + rifampicin MRSA Additive
100  Daptomycin + gentamicin + rifampicin MRSA Additive
97  Linezolid + vancomycin GISA Additive
94  Linezolid + vancomycin MSSA/MRSA Antagonistic
89, 95 Linezolid + vancomycin MRSA Indifferent
101  Linezolid + vancomycin MSSA/MRSA/MRSE Increased killing
94, 98 Linezolid + gentamicin MSSA/MRSA Indifferent
95  Linezolid + gentamicin MRSA Antagonistic
94  Linezolid + rifampicin MSSA/MRSA Indifferent
95  Linezolid + rifampicin MSSA/MRSA Synergistic
102  Linezolid + rifampicin MSSA Indifferent
101  Linezolid + quinupristin/dalfopristin MRSA Increased killing
97  Quinupristin/dalfopristin + vancomycin GISA Additive-Synergistic
103  Quinupristin/dalfopristin + vancomycin MSSA/MRSA Additive
101  Quinupristin/dalfopristin + vancomycin MRSA Increased killing
92  Quinupristin/dalfopristin + vancomycin MSSA/MRSA Synergistic
97  Quinupristin/dalfopristin + gentamicin GISA Indifferent
104  Quinupristin/dalfopristin + rifampicin MSSA Increased killing
105  Quinupristin/dalfopristin + rifampicin MRSA Synergistic
106  Tigecycline + vancomycin MRSA Indifferent
107  Tigecycline + gentamicin MRSA/GISA Increased killing
106  Tigecycline + rifampicin MRSA Indifferent
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On the other hand, antagonistic interactions were dem-
onstrated for the combination of linezolid plus vancomycin,94 
and linezolid plus gentamicin.95 It should be emphasized 
that in vitro interaction may not translate into clinical ef-
ficacy. Quinupristin/daflopristin in combination with van-
comycin appeared to be favourable for the management 
of MRSA infections responding poorly to vancomycin.96 
However, we have to specify that the MRSA isolates were of a 
specific genotype, accessory gene regulator (agr), which has 
been linked to vancomycin treatment failure.96 Nevertheless, 
such information may be useful if innovative combination 
therapy needs to be administered to severely ill patients with 
invasive S. aureus infection unresponsive to monotherapy.
Controlled clinical trials using combinations including 
these new agents are indicated for patients with severe, life-
threatening infections caused by gram-positive cocci, and 
randomized trials are strongly warranted in this somewhat 
unexplored field.
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